Venetoclax is a first-in-class, potent, oral B-cell lymphoma (BCL-2) inhibitor that is approved for treatment of chronic lymphocytic leukemia (CLL) and adult AML 7 and is currently under development for several other hematological malignancies including ALL, multiple myeloma (MM), mantle cell lymphoma (MCL) and pediatric AML 8. Here, BCL2 is linked to acute lymphoblastic leukemia.